Mirela Anghelina

The Ohio State University — United States

Medicine · Health Sciences

24h-index2.2kcitations60works5.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(20), Lymphoma Diagnosis and Treatment(10), Immunodeficiency and Autoimmune Disorders(9), Acute Lymphoblastic Leukemia research(7), Immune Cell Function and Interaction(7)

Publications60 total

194 | A NOVEL APPROACH FOR CLASSIFICATION OF SPLENIC B CELL LYMPHOMA USING DNA METHYLATION REVEALS DIVERSE BIOLOGICAL DISEASE MECHANISMS
Hematological Oncology·2025Open Access
Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia
eJHaem·2024· 3 citedOpen Access
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
Leukemia·2024· 13 citedOpen Access
DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma
Blood·2023· 2 citedOpen Access
Increased COVID-19 Mortality and Deficient SARS-CoV-2 Immune Response Are Not Associated with Higher Levels of Endemic Coronavirus Antibodies
Immuno·2023· 3 citedOpen Access
Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2
eJHaem·2023· 2 citedOpen Access
Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants
Cell Reports Medicine·2023· 29 citedOpen Access
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
Cell Reports·2023· 183 citedOpen Access
Impact of sex on outcomes in patients with hairy cell leukemia. An <scp>HCL</scp> patient data registry analysis
American Journal of Hematology·2023· 13 citedOpen Access
Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
2023· 49 citedOpen Access
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
Cell Host & Microbe·2022· 278 citedOpen Access
Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment
Blood·2022
Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia
Blood·2022· 4 cited
Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues
Blood·2022· 1 cited
Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
2022· 87 citedOpen Access
Development of a distributed international patient data registry for hairy cell leukemia
Leukemia & lymphoma/Leukemia and lymphoma·2022· 3 citedOpen Access
Corrigendum to “Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia” [Leuk. Res. 120 (2022) 106919]
Leukemia Research·2022Open Access
Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia
Leukemia Research·2022· 2 citedOpen Access
COVID-19 Booster Uptake among First Responders and Their Household Members May Be Lower than Anticipated
Vaccines·2022· 2 citedOpen Access
Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.
Journal of Clinical Oncology·2022· 2 cited
page 1 of 3Next →

Frequent Co-authors

Gerard Lozanski(15), Kerry A. Rogers(14), James S. Blachly(14), Michael R. Grever(14), Leslie A. Andritsos(13), Leni Moldovan(9), Nicanor I. Moldovan(9), Sudha Agarwal(9), Soledad Fernández(8), Seema A. Bhat(8), William E. Carson(7), Christopher C. Oakes(7), Narendranath Epperla(7), Ashish R. Panchal(6), Linda J. Saif(6), Eugene M. Oltz(6), Shan‐Lu Liu(6), Versha Banerji(6), Clive S. Zent(6), Qiuhong Zhao(6)